n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, January 2nd, 2018

The QualityStocks
Daily Stock List

graphic
graphic

Synergy CHC Corp. (SNYR)

OTC Markets, SmallCapVoice, MarketWatch, and TradingView reported previously on Synergy CHC Corp. (SNYR), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Synergy CHC Corp. is a consumer health care company based in Westbrook Maine. It is in the process of building a portfolio of best-in-class consumer product brands. The Company’s strategy is to increase its portfolio organically and through further acquisition. Formed in 2012, Synergy CHC lists on the OTC Markets Group’s OTCQB.

The Company sells its products chiefly in North American retail locations. Its diversified portfolio includes FOCUSFactor™, Flat Tummy Tea™, Per-fékt Beauty™, Sneaky Vaunt™, The Queen Pegasus™, Neuragen™, and Hand MD™.

Flat Tummy Tea™ is a uniquely formulated two-step herbal detox tea. It works to naturally help speed up metabolism, boost energy, and lessen bloating to flatten one’s stomach/tummy.

FOCUSFactor is a nutritional supplement. It includes a proprietary blend of brain supporting vitamins, minerals, antioxidants, as well as other nutrients.

Neuragen® is a topical product. It works directly at the site of the pain contrasted with oral products. Neuragen® decreases the spontaneous firing of damaged peripheral nerves.

Synergy CHC’s Hand MD® is the world's first anti-aging skincare line formulated specifically for the hands. Furthermore Synergy CHC has launched its newest brand, Sneaky Vaunt.

Synergy CHC officially launched The Synergy Effect, its ROI (Return on Investment) innovation engine and online marketing platform. The Synergy Effect was built to drive online revenue growth for all of the Company’s brands.

Synergy CHC announced in June 2017 that it entered into, and at the same time closed on, an Asset Purchase Agreement with Per-fekt Beauty Holdings, LLC and CDG Holdings, LLC, which owns 92.3 percent of the issued and outstanding equity interests of Per-fekt Beauty. Per-fekt Beauty engages in developing and selling skincare and cosmetics products under the brand Per-fekt.

With the Purchase Agreement, Synergy CHC purchased all of Per-fekt Beauty's assets and assumed certain of its liabilities for a purchase price of $709,988.34. As additional consideration, it will pay quarterly royalties equal to 5 percent of Net Sales for 10 years following the closing date.

In October 2017, Synergy CHC announced the appointment of Mr. Patrick McCullough to the Company’s management team as President. Mr. McCullough previously was the Chief Commercial Officer for InterHealth Nutraceutical Incorporated. Before joining InterHealth, he worked for Corr-Jensen. In addition, he was the President of Natrol Corp.

In November 2017, Synergy CHC reported results for the quarter ended September 30, 2017. In the quarter, the Company launched The Queen Pegasus, which is a lash elixir kit sold using The Synergy Effect. In addition, Synergy CHC secured $10 million of funding from Knight Therapeutics (Barbados), Inc. with the potential to increase to $30 million.

Net Sales for Q3 were $9.2 million, versus $11.5 million for the same quarter in 2016. This represents a 20 percent decrease. For Q3, the Company’s Net Income was $0.01 million or $0.00 (basic and diluted) earnings per share. This is in comparison to Net Income of $3 million or $0.04 (basic and diluted) earnings per share for 2016.

Net Sales for the nine months ended September 30, 2017 were $29.3 million, versus $28 million for the same period in 2016. This represents a 4.6 percent increase. For the nine months ended September 30, 2017, Net Income was $2.6 million, or $0.03 (basic and diluted) earnings per share, versus Net Income of $5.8 million or $0.07 (basic and diluted) earnings per share for the same period in 2016.

Synergy CHC Corp. (SNYR), closed Tuesday's trading session at $0.49, up 0.56%, on 18,155 volume with 6 trades. The average volume for the last 60 days is 13,499 and the stock's 52-week low/high is $0.281/$0.80.

AmpliTech Group, Inc. (AMPG)

Trading Wall St, fusionspicks, Jet-Life Penny Stocks, OTCMagic, Ascending Stocks, Penny Stock Gainers, RockingPennyStocks, BestStocksDaily, Wallstreetbuzz, AllPennyStocks, SmallCapVoice, PennyStocks24, Information Solutions Group, Pumps and Dumps, HoleinOneStocks.net, HotStockProfits, and Fortune Penny Stocks reported on AmpliTech Group, Inc. (AMPG), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF Low Noise Amplifiers (LNA) and Power Amplifiers (PA). These are for the domestic and global, SATCOM, Space, and Military markets. Additionally, the Company provides consulting services to help with any microwave components or systems design problems. AmpliTech sells its products by way of sales representatives and distributors in North America, Europe, and Asia. OTCQB-listed, AmpliTech Group is based in Bohemia, New York.

The Company’s designs cover the frequency spectrum from 50 kHz to 40 GHz – eventually providing designs up to 100 GHz. AmpliTech can provide complex, custom solutions for almost any custom requirements presented to it. It can provide contract assembly of customers' own designs.

AmpliTech provides its customers with consulting services for their system development. In addition, the Company provides technical assistance in integration and packaging technologies and microwave sub-systems and amplifier related sub-assemblies.

AmpliTech utilizes the most contemporary CAD microwave simulation technology to design and develop from concept to final manufacture of a deliverable product with first-rate accuracy. AmpliTech expects to release new products targeted at the wireless and satellite markets, which will provide advanced technology and performance.

AmpliTech Group announced in 2017 that it entered into a Joint Venture (JV) Agreement with Trusted Networks, Inc. (TN). TN is a New York, New York based private company with facilities in Colorado Springs and Nashua, New Hampshire.

The emphasis of this JV is to develop an affordable mixed signal chipset that can be used at server/router level and also in mobile PDA applications to provide secure and encrypted communication with the goal of preventing hacking and cyber-attacks.

This JV will take advantage of AmpliTech's industry leadership and experience in RF/Microwave LNA technology and TN's Cyber-security Protocol technology to eliminate the widespread occurrence of corporate and individual cyber-attacks.
In November, Amplitech Group announced the filing of its 10-Q for Q3 2017. AmpliTech reported a decline in gross revenues of 24 percent versus the same period the year prior. The Company experienced its second consecutive quarter with reduced revenue.

However, AmpliTech continued its path towards enhancing and expanding its niche product line and technology through investing in research and development (R&D) in higher margin products for commercial applications. In addition, AmpliTech has invested substantially more into advertising and marketing than any other year in its history.

AmpliTech Group, Inc. (AMPG), closed Tuesday's trading session at $0.03594, up 12.31%, on 40,200 volume with 5 trades. The average volume for the last 60 days is 60,377 and the stock's 52-week low/high is $0.0296/$0.11.

Generex Biotechnology Corporation (GNBT)

MicroCap Daily, InvestorsHub, OTC Markets, StreetInsider, Stockhouse, Insider Financial, and Zacks reported on Generex Biotechnology Corporation (GNBT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical enterprise, Generex Biotechnology Corporation engages in the discovery, research, development, and financing of new compounds, therapies, diagnostics, delivery systems, and medical technologies. The Company’s main emphasis has been its proprietary technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity utilizing a handheld aerosol applicator. Generex Biotechnology has offices in Burlington, Ontario, and Miramar, Florida. The Company lists on the OTCQB.

Generex Biotechnology has two business focuses. One is implementing an acquisition strategy. The second is financing sponsored clinical trials. The Company is positioning its business as a diversified holding company involved in growing its pipeline of compounds, therapies, treatments, diagnostics, and technologies in all stages in the Food and Drug Administration (FDA) process via accretive acquisitions.

Generex Oral-lyn is an insulin spray for the treatment of Type I and Type II diabetes. The Company states that Generex Oral-lyn is a safe, simple, fast, effective, and pain-free alternative to subcutaneous injections of prandial insulin. It is conveniently delivered to the membranes of the oral cavity through a simple asthma-like device with no pulmonary (lung) deposition.

RapidMist is an advanced buccal drug delivery technology. It consists of a proprietary formulation and a proprietary device design, which can deliver drugs by way of the buccal mucosa safely. Therefore, this eliminates the pain from and need for numerous injections. RapidMist has been shown to have a rapid onset of action with no lung deposition, precise dosage control, easy use and handling, and improved patient compliance.

This past October, Generex Biotechnology announced that its subsidiary, Hema Diagnostic Systems, LLC, entered into an exclusive contract with Imerlab Sociedad Comercial Limitada for the distribution and sale of the Rapid 1-2-3® Hema HIV EXPRESS® diagnostic test in the Republic of Chile. The Chilean Ministry of Health has registered the Rapid 1-2-3® Hema HIV EXPRESS®. It has been approved for sale there.

Imerlab Sociedad Comercial will have the exclusive rights to negotiate with private entities and public institutions for the placement and sale of the product in clinical settings that require fast point-of-care (PoC) testing for HIV, not only in urban hospital and outpatient clinics, but also in parts of the nation that have limited laboratory and testing resources.

In December, Generex Biotechnology announced that its wholly-owned subsidiary, Antigen Express, Inc., entered into a License and Research Agreement with Shenzhen BioScien Pharmaceuticals Co. Ltd. to develop and commercialize the Antigen Express AE37 immunotherapeutic vaccine for prostate cancer in the People’s Republic of China (including Taiwan, Hong Kong, and Macau).

Shenzhen BioScien Pharmaceuticals will pay Generex Biotechnology a non-refundable, up-front license fee of $700,000 USD. With this Agreement, Shenzhen BioScien Pharmaceuticals will also make milestone payments to Generex Biotechnology of $1,000,000 USD each upon completion of the Phase II and Phase III clinical studies of the vaccine and a milestone payment of $2,000,000 USD upon regulatory approval of the vaccine in the territory. In addition, Generex Biotechnology will receive a 10 percent royalty on Net Sales of the product.

Generex Biotechnology will hold an investor conference call at 10:30 a.m. Eastern time on Thursday, January 4, 2018. The purpose of this conference call will be to provide investors with an update on its initiatives and strategic plans. This includes its capital reorganization, its controlling interest in Hema Diagnostic Systems, LLC, the recently announced initiatives of Antigen Express, Inc., the Company’s wholly-owned immuno-therapeutics subsidiary, with Merck Sharp & Dohme B.V. and Shenzhen BioScien Pharmaceuticals Co. Ltd., and the Company’s buccal drug delivery platform technologies.

Generex Biotechnology Corporation (GNBT), closed Tuesday's trading session at $2.89, up 4.71%, on 6,887 volume with 33 trades. The average volume for the last 60 days is 3,077 and the stock's 52-week low/high is $2.00/$20.00.

Barsele Minerals Corp. (BRSLF)

Stockhouse, Stock Press Daily, The Stock Talker, TradingView, The Wall Street Review, and MarketWatch reported on Barsele Minerals Corp. (BRSLF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Incorporated in 2013, Barsele Minerals Corp. is a junior mineral exploration company headquartered in Vancouver, British Columbia. The Company has a notable gold, silver, and copper exploration project on renowned mineral trends in Sweden (the Barsele Gold Project). Its advanced-stage Barsele Gold Project is near Storuman, Västerbottens Län, which is roughly 600 kilometers north of Stockholm, Sweden. Barsele Minerals’ shares trade on the OTC Markets Group’s OTCQB.

The Company’s management team is a part of the Belcarra Group. This team has received recognition for the discovery of Orko Silver Corp.’s La Preciosa Silver-Gold Deposit in Durango, Mexico, among other discoveries.

Barsele Minerals is a joint venture (JV) partner with Agnico Eagle on the Barsele Gold Project. Agnico Eagle owns 55 percent and Barsele Minerals owns 45 percent. Agnico Eagle has an option to increase to 70 percent through taking the
Project to Pre-Feasibility (Ongoing). Furthermore, Orex Minerals, Inc. holds a 2 percent NSR (Net Smelter Return) that can be purchased for US $5M. All exploration costs prior to Pre-Feasibility are covered by Agnico Eagle.

The Barsele Gold Project is in a region with current and past producers. These are Boliden, Kristineberg, Bjorkdal, and Svartliden. Barsele Minerals also has additional JVs in Sweden, as well as knowledgeable and well connected staff already in Scandinavia.

For 2017, Agnico Eagle considerably increased exploration and the drilling program over the prior year. Infill drilling continues to connect Avan, Central and Skirasen zones extending the main area of mineralization to greater than 3 kilometers. Drilling at Risberget, 3.7 kilometers to the southeast of Skirasen, yielded 4 significant gold hits and metallurgical testing yielded recovery rates of more than 92 percent.

In November, Barsele reported an operational update for the continuing exploration program within the Barsele Gold-VMS Project area in Västerbottens Län, northern Sweden. Nine holes were reported, of which six were expansion, two were infill and one was a regional test. One hole was abandoned because of bad ground conditions.

Since the start of drilling in late 2015 and until the end of the month of September 2017, 86,310 meters of core has been collected from 191 drill holes. Base of till sampling is ongoing.

Agnico Eagle's recent surface extension trenching program was completed. Structural mapping along the 90.0 meter by 15.0 meter corridor validates the existing gold distribution model and provides detailed information on quartz veining and reactivation of the different shearing and mineralization orientations. The information will help with the continuing modeling of the gold deposit.

Barsele Minerals Corp. (BRSLF), closed Tuesday's trading session at $0.514, down 1.21%, on 4,000 volume with 1 trade. The average volume for the last 60 days is 17,716 and the stock's 52-week low/high is $0.4186/$1.2466.

International Frontier Resources Corporation (IFRTF)

MarketWatch, Stockhouse, Marketwired, 4-Traders, and Emerging Growth reported on International Frontier Resources Corporation (IFRTF), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

International Frontier Resources Corporation has a demonstrated record of accomplishment advancing oil and gas projects. The Company, by way of its Mexican subsidiary, Petro Frontera S.A.P.I de CV and strategic joint ventures (JVs) is advancing the development of petroleum and natural gas assets in Mexico. International Frontier Resources is based in Calgary, Alberta and the Company’s shares trade on the OTC Markets Group’s OTCQB.

International Frontier Resources (IFR) has projects in Canada and the United States, including the Northwest Territories and the State of Montana. In 2015, IFR created a JV company - Tonalli Energia - together with Grupo Idesa, one of Mexico’s largest petrochemical companies. IFR and Grupo Idesa are fully aligned; each owns a 50 percent share in Tonalli.

An industry-leading JV combines the strength of Grupo Idesa and IFR. Grupo Idesa is a well-established Mexican petrochemical company. In addition, IFR brings proven Canadian expertise to Mexico.

Block 24 Tecolutla establishes IFR’s Mexican JV as one of the first operators in Mexico and provides important insights into future rounds. Tecolutla is a very underdeveloped mature field with considerable upside potential.

Tonalli has submitted the regulatory applications and documentation, which will permit IFR to proceed with the drilling permit and operations at Tecolutla. The Tecolutla Block is in the Tampico-Misantla Basin within the State of Veracruz.

The Tecolutla Field is 7.2 square kilometers. It contains an oil reservoir at 2,340 meters or about 7,700 feet. The Tecolutla Block is a 60-80m gross pay carbonate reservoir on a structural high with proven oil production.

The expectation is that the existing wells at Tecolutla will exceed historic production numbers and peak initial production (IP) rates with the arrival of new recovering techniques, technology, and expertise to be undertaken by Tonalli.

Last month, International Frontier Resources announced that it received total proceeds of $2,561,045 from the exercise of warrants by members of the Executive and Technical team, Board of Directors and investment community. The Company issued an additional 24,961,880 common shares from its Treasury via the conversion of these warrants to shares.

Mr. Steve Hanson, International Frontier Resources’ President and Chief Executive Officer, stated, “We are pleased to have received a considerable investment in our business from our team, board members and the investment community. This additional capital will allow us to accelerate our business, further our development plans at Tecolutla and participate in future bid rounds in Mexico."

International Frontier Resources Corporation (IFRTF), closed Tuesday's trading session at $0.145, down 4.61%, on 32,690 volume with 17 trades. The average volume for the last 60 days is 29,807 and the stock's 52-week low/high is $0.112/$0.31.

Abtech Holdings, Inc. (ABHD)

Greenbackers, Stealth Stocks, Wyatt Investment Research, Investor Ideas, Stock Mister, OTC Journal, The Stock Psycho, Wall Street Resources, FeedBlitz, Topgun stockpicks, Hidden Values Alert, CoolPennyStocks, and AllPennyStocks reported earlier on Abtech Holdings, Inc. (ABHD), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Abtech Holdings, Inc. is a full-service environmental technologies and engineering company. It provides creative solutions to communities, industry, as well as governments addressing issues of water pollution and contamination. Abtech provides solutions for Stormwater Management, Oil & Gas Water Treatment, and Industrial Water Treatment. OTCQB-listed, Abtech Holdings is based in Scottsdale, Arizona. AbTech Industries, Inc. is a subsidiary of Abtech Holdings.

Abtech began marketing of produced water and industrial wastewater treatment, and established its engineering subsidiary AEWS Engineering in 2012. AEWS is an independent civil and environmental engineering firm partnered with foremost research and engineering universities.

The foundation of Abtech’s products is on polymer technologies, which can remove hydrocarbons, sediment, and other foreign elements in stormwater runoff, flowing water, and industrial process and wastewater. Abtech’s products include advanced filtration media technologies and different water treatment systems.

The Company’s offerings include the antimicrobial technology- Smart Sponge® Plus. This technology is effective in reducing coliform bacteria found in stormwater, industrial wastewater, and municipal wastewater. Smart Sponge® Plus is registered with the Environmental Protection Agency (EPA).

Abtech has installed and validated onsite its first mobile water pre-treatment system centered on oil recovery and hydrocarbon removal for the treatment of flowback and produced water for the on-shore Oil & Gas industry. This pre-treatment system integrates its Smart Sponge® technology. The design of it is to operate in advance of other treatment systems, boosting overall efficiency and lessening treatment cost.

Abtech Holdings continued its activity in 2017 with several water treatment field trials. It prepared for the second field test of evaporative technology for produced and frac flowback water with a concentration on emissions. It successfully completed a Smart Sponge® hydrocarbon removal and recycling of spent media demonstration in a produced water application for its Colombian distributor, advancing discussions to economics and design issues. In addition, it achieved low phosphorus results on a sanitary wastewater application in China.

In July 2017, Abtech Holdings announced that it and United Stormwater, Inc. collaborated to bring two best-in-class technologies together, providing an inventive solution for developing stormwater challenges in southern California.

A municipality in Los Angeles County, California retrofitted existing infrastructure using United Stormwater's Wing-Gate™ Screens, auto-retractable curb inlet screen covers, and Abtech's Ultra-Urban® Filters, catch basin inserts, so as to prevent stormwater contamination that flows into Legg Lake, one of Los Angeles County's biggest and most popular recreation areas. United Stormwater is a full service stormwater management company.

Abtech Holdings, Inc. (ABHD), closed Tuesday's trading session at $0.0145, down 9.38%, on 167,150 volume with 11 trades. The average volume for the last 60 days is 45,886 and the stock's 52-week low/high is $0.0061/$0.024.

Midwest Energy Emissions Corp. (MEEC)

MissionIR, SeriousTraders, TopPennyStockMovers, Greenbackers, Marketbeat, Wall Street Resources, NBT Equities Research, and PennyStocks24 reported on Midwest Energy Emissions Corp. (MEEC), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Midwest Energy Emissions Corp. is a developing leader in mercury emissions control technology for the worldwide coal-power industry. The Company develops and employs patented and proprietary technologies to remove mercury from coal-power plant emissions. Midwest Energy Emissions concentrates on the delivery of mercury capture technologies to power plants and other industrial coal-burning units in North America, Europe, and Asia. The Company has its corporate office in Lewis Center, Ohio.

Midwest Energy Emissions utilizes patented technology that has been shown to attain mercury removal levels compliant with the U.S. Environmental Protection Agency's (EPA) Mercury and Air Toxic Standards (MATS) rule, at an appreciably lower cost and with less operational impact than methods now used. This is while preserving the ability for customers to recycle and sell fly-ash for beneficial use.

The Company’s proprietary SEA™ (Sorbent Enhancement Additive) technology delivers a flexible, tunable solution. It permits the global coal-power industry to easily comply with new, highly restrictive regulations on mercury air emissions. The SEA™ approach to mercury capture is precisely tailored for each application to complement a customer’s fuel kind and boiler configuration for best results.

Midwest Energy Emissions has acquired all patent rights for its Sorbent Enhancement Additive (SEATM) mercury emissions control technology from the Energy & Environmental Research Center Foundation (EERCF of Grand Forks, North Dakota). It acquired the rights for $2.5 million and 925,000 shares of common stock in Midwest Energy Emissions. EERCF is an organization that works to provide innovative solutions to the world’s energy and environmental challenges.

Recently, Midwest Energy Emissions provided its financial results for Q3 ended September 30, 2017. Total Revenues in Q3 2017 were $8.4 million versus $11.8 million in Q3 2016. This decrease is mainly because of optimization efforts undertaken over the past year with the Company’s customers and also lower capacity factors seen at some customer sites resulting in reduced product needed to keep its customers in MATS compliance.

Operating Income in Q3 2017 was $1.0 million, versus an Operating Income of $1.7 million in Q3 2016. This decrease was mainly because of lower product sales over the same quarter the year prior. Net Income in Q3 2017 was $0.9 million, or $0.01 per diluted share, versus a Net Loss of $9.3 million, or ($0.19) per diluted share, in Q3 2016.

Midwest Energy Emissions secured its first contract in Canada this past October. The initial purchase order, valued at roughly $700,000, will include the installation of its proprietary Sorbent Enhancement Additive (SEA™) Technology servicing the front end of four new electric generating units (EGUs). Midwest Energy Emissions expects further geographic expansion to help smooth out seasonal fluctuations that are usually experienced because of varying power demands.

Midwest Energy Emissions is adding a new product to its proven, cost-effective mercury capture program, which will lessen mercury emissions by preventing scrubber reemission events. The design of the product is specifically for coal-fired power utilities with wet scrubbers to help remove mercury and other metals from the scrubber.

Midwest Energy Emissions Corp. (MEEC), closed Tuesday's trading session at $0.26, up 5.91%, on 32,769 volume with 8 trades. The average volume for the last 60 days is 75,384 and the stock's 52-week low/high is $0.20/$1.43.

graphic

The QualityStocks
Company Corner

graphic
graphic

EVIO, Inc. (EVIO)

The QualityStocks Daily Newsletter would like to spotlight EVIO, Inc. (EVIO). Today, EVIO, Inc. closed trading at $2.14, up 57.35%, on 603,104 volume with 949 trades. The stock’s average daily volume over the past 60 days is 58,595, and its 52-week low/high is $0.47/$3.20.

EVIO, Inc. (EVIO) announced today that it completed the acquisition of 60% of C3 Labs, LLC.  EVIO also has the option to purchase the remaining ownership subject to terms disclosed below.  Effective January 1, 2018, C3 Labs LLC was also granted its temporary testing license from the State of California, and will operate under the brand EVIO Labs Berkeley.

EVIO, Inc. (EVIO), via the EVIO Labs division, is the nation's leading provider of accredited analytical testing, scientific research and advisory services to the regulated cannabis industry. EVIO Labs provides state-mandated ancillary services that are required to ensure the safety and quality of the nation's cannabis supply. EVIO Labs has performed over 50,000 tests during the past two years and grown from one laboratory in Oregon to nine labs spanning California, Oregon, Colorado, Massachusetts and Florida.

EVIO Labs is driving the cannabis testing industry by providing clients nationwide with consistent high-quality cannabis analytical services backed by quality control assurances. The company also provides advisory services that help cannabis producers and retailers enhance production processes, achieve regulatory compliance and meet quality goals.

EVIO Labs is on track to open 18 laboratories by the end of 2018 at locations around the United States. The Oregon-based company provides analytical services that include testing cannabis and industrial hemp flower, extracts and infused products. The labs specialize in performing the following tests:

  • Cannabinoid analysis, which properly characterizes the many primary cannabinoids found in cannabis including THC, CBD, and several other cannabinoids.
  • Terpene analysis, which identifies the aromatic compounds of the plant (terpene), which can help identify the therapeutic potential of a cannabis flower or extract.
  • Moisture content and water activity, which measure the moisture levels of dried cannabis and are indicators of microbiological growth potential.
  • Pesticide residue analysis of over 100 different pesticides, herbicides, fungicides, growth regulators and other agrochemicals that may be present on cannabis.
  • Detection of harmful residual solvents left behind in the cannabis extract production process.
  • Microbial testing screen for bacterial and fungal contamination in cannabis and cannabis-infused products.
  • Detection of heavy metals including lead, cadmium, mercury, and arsenic.

EVIO Labs is rapidly becoming the nation's leading cannabis biotechnology company. Led by a management team with extensive experience in designing and rolling out successful business ventures, product research and development, regulatory and compliance protocols, medical cannabis cultivation, production and analytical chemistry techniques, EVIO Labs is prepared to take advantage of today's fastest growing industry. Disclaimer

EVIO, Inc. Company Blog

EVIO, Inc. News:

EVIO Inc. Completes Acquisition of Licensed California Cannabis Testing Laboratory

EVIO Labs Colorado Licensee Announces ISO 17025 Accreditation

EVIO Inc. to Purchase Licensed Cannabis Laboratory in Northern California

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF)

The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $1.39, up 13.93%, on 950,194 volume with 832 trades. The stock’s average daily volume over the past 60 days is 444,156 and its 52-week low/high is $0.6171/$1.42.

ABcann Global (TSX.V:ABCN) (OTCQB:ABCCF) is pleased to announce that the Company has been licensed by Health Canada to produce medical cannabis oils. Once ABcann has saleable extracted finished products, Health Canada will conduct a final inspection to approve the sale of cannabis oils by the Company. This is expected in the first quarter of 2018.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global Announces Receipt of Health Canada License to Produce Cannabis Oils

ABcann Enters into Agreement to Acquire Leading Medical Cannabis Clinic

ABcann Global Announces Financial Results and Provides Operational Update

ChineseInvestors.com, Inc. (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com, Inc. (CIIX). Today, ChineseInvestors.com, Inc. closed trading at $0.85, up 4.29%, on 185,510 volume with 149 trades. The stock’s average daily volume over the past 60 days is 220,988 and its 52-week low/high is $0.40/$2.75.

ChineseInvestors.com (CIIX) today provides a post-holiday update on CBD Biotechnology Co. Ltd.'s Yantai 1985 baijui sales. ChineseInvestors.com, Inc.'s wholly owned foreign enterprise, CBD Biotechnology Co. Ltd. has partnered with a proven leader in the Chinese baijiu market, China GuiZhou HanTai Wine, Inc., and based on its initial marketing campaign, anticipates revenues of 12,000,000 CNY, or $1,800,000 USD in 2018. Baijiu is a Chinese liquor made from grains or rice. Baijiu is about 104 proof (52% alcohol).

Founded in 1999, ChineseInvestors.com, Inc. (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer

ChineseInvestors.com, Inc. Blog

ChineseInvestors.com, Inc. News:

CannabisNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Provides Post-Holiday Update on Baijiu Sales

NetworkNewsAudio Covers ChineseInvestors.com’s Release on Recent Interview on Top-Rated Cryptocurrency Podcast

Top-Rated Cryptocurrency Podcast, "Bad Crypto Podcast" Features Interview with ChineseInvestors.com, Inc.'s CEO, Warren Wang

MGX Minerals Inc. (MGXMF)

The QualityStocks Daily Newsletter would like to spotlight MGX Minerals Inc. (MGXMF). Today, MGX Minerals Inc. closed trading at $0.78, up 0.52%, on 180,595 volume with 80 trades. The stock’s average daily volume over the past 60 days is 144,222 and its 52-week low/high is $0.43/$2.119.

MGX Minerals Inc. (MGXMF) is pleased to announce that the site survey, in preparation for 3D seismic geophysics, at the Company’s Paradox Basin Petrolithium Project, has been completed. The site survey covers the Company’s Blueberry Unit within its Utah Petrolithium portfolio (the “Project”). The survey includes approximately 9,000 source points. The purpose of the geophysical survey is to outline subsurface geological formations and structures favorable for accumulations of oil and gas as well as lithium brine bearing formations.

MGX Minerals Inc. (CSE: XMG) (FKT: 1MG) (OTCQB: MGXMF) is a diversified Canadian resource company developing large-scale mineral portfolios in specific commodities and jurisdictions in North America. The company controls significant interest in lithium, magnesium and silicon assets that offer streamlined development timelines and low capital expenditures. MGX Minerals and its engineering partner have developed a patent-pending, low-energy design process to extract valuable minerals from the abundant, highly mineralized brine wastewater produced each year by oil and gas companies.

This proprietary, petrolithium process rapidly concentrates lithium and other minerals from brine in less than a day. That's a stunning advancement from the conventional method of extracting minerals from brine through an evaporation process that can take up to 18 months, requires hundreds of acres of land, and averages less than a 50 percent mineral recovery rate. Using this advanced water purification technology, MGX Minerals cleans the wastewater that accompanies petroleum as it's being pulled up to the surface. The company's petrolithium process eliminates the need to inject contaminated wastewater back into the ground, which prevents drinking water contamination and possible earthquakes.

In January 2017, MGX Minerals successfully recovered concentrated lithium from heavy oil evaporator blowdown wastewater using its rapid recovery process, an accomplishment independently confirmed by the Saskatchewan Research Council. In August 2017, the company also successfully processed wastewater and lithium brine from eight North American projects at its one-cubic-meter-per-hour processing plant, proving the technology is economically viable. Research group Global Water Intelligence expects the wastewater treatment industry to grow into a $45 billion market annually by 2025, which suggests there are ample revenue-generating opportunities for MGX Minerals technology.

Lithium, the "white gold" of the new energy economy, is the key to clean energy development as global demand for hybrid and electric vehicles, high-drain portable electronic devices, and large-scale energy storage systems ramps up. Grand View Research, Inc. reports that the global lithium-ion battery market is expected to reach $93.1 billion by 2025. Current market forces show a high demand for lithium and a low supply, which further supports the necessity of MGX Mineral's cleaner, faster method of extracting high-value minerals from brine wastewater.

MGX Minerals is led by a team of industry standout performers who have worked in the mining and technology industries for decades. The leadership team is joined by an array of top-notch technical partners with unmatched experience in the oil and gas sectors, environmental services industry, marketing and product development, along with applied research and commercial development of technologies. Disclaimer

MGX Minerals Inc. Blog

MGX Minerals Inc. News:

MGX Minerals Announces Completion of Site Survey for 3D Seismic Geophysics at Paradox Basin, Utah Petrolithium Project

MGX Minerals Commences Exploration and Permitting at Kootenay and Wonah Silicon Projects; Metallurgy Process Design for Testing of Solar Grade Silicon Applicability Completed

MGX Minerals Advances 110,000 Acre Petrolithium Project Paradox Basin, Utah

Veritas Pharma, Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP)

The QualityStocks Daily Newsletter would like to spotlight Veritas Pharma, Inc. (VRTHF). Today, Veritas Pharma, Inc. closed trading at $0.7015, off by 2.50%, on 605,690 volume with 434 trades. The stock’s average daily volume over the past 60 days is 205,323 and its 52-week low/high is $0.22/$0.881.

Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (FRT:2VP) is pleased to announce that Dr. Brian O’Connor, a consultant in respiratory medicine, has joined its advisory board. He is a clinical expert in the areas of asthma, Chronic Obstructive Pulmonary Disease (“COPD”), allergic disease, and lung cancer; in addition to, being an active clinical researcher committed to investigating new treatment strategies in Airways Disease.

Veritas Pharma, Inc. (CSE: VRT) (OTCQB: VRTHF) is an emerging pharmaceutical and IP development company publicly traded in Canada, the United States and Germany. Through its recently acquired 80 percent stake in Cannevert Therapeutics Ltd., also known as Veritas' R&D arm, the company is clinically profiling various marijuana cultivars to pharmacologically connect unique strains with specific disease conditions. Veritas Pharma's goal is to perform clinical trials to prove the efficacy of the designated lead cannabis strains and to market the clinically effective cultivars as prescription medicines in a fast-track protocol.

Veritas Pharma's management and R&D team comprises decades of pharmaceutical, clinical and scientific research expertise into several key industry leaders. Lui Franciosi, PhD, who has over 20 years of experience conducting pharmaceutical and medical device studies in academia and industry, leads the company as its CEO. In addition to a team of trained technicians and students working out of academic facilities, Veritas Pharma is pleased to have a renowned group of scientists on board to lead its research efforts. Team members hold 10 PhDs/MD licenses with expertise in chemistry, pharmacology and clinical trials.

Veritas Pharma's mission is to develop and commercialize the most effective cannabis strains, backed by clinical data. This innovative research and development path aims to solve the critical need for real science to support claims surrounding medical marijuana. The company's approach, combined with its strategic alliances, will effectively address the medical community's concerns over the complexities of cannabis potency, efficacy, quality and content in the nearly 800 marijuana strains currently known in the world. Opportunities for innovation and scientific advancement related to the field of cannabis therapeutics will accelerate the knowledge base and provide a valuable alternative to the global opioid market that is estimated at nearly U.S. $35 billion. A growing negative opinion regarding the use of opioids for pain will continue to drive the need for alternative medical applications such as those provided by cannabis.

Veritas Pharma's clinical cannabis development pipeline includes R&D for chronic pain, nausea, inflammation, muscle spasms, epilepsy and Post Traumatic Stress Disorder. The strategic alliance formed with Cannevert and its scientists will enable Veritas to be at the forefront of developing new and unique strains of medicinal cannabis. These plants, which they plan to patent protect for a variety of unmet medical needs, are destined to help patients suffering with chronic and debilitating symptoms of a variety of medical issues. Over 250 experiments have been performed so far with another 150 pharmacological and biological studies conducted. Veritas Pharma has also entered into an agreement with Sechelt Organic Marijuana Inc., which has a Licensed Producer application pending with Health Canada, to acquire 100 percent ownership in the company.

Results of the company's research to date illustrate Veritas' unique place in the medical marijuana industry. The company's focus on the biological effect of the actual spectrum of cannabinoids sets Veritas apart as it seeks to patent and protect results-driven strains. Disclaimer

Veritas Pharma, Inc. Blog

Veritas Pharma, Inc. News:

Dr. Brian O’Connor Joins Veritas Pharma Advisory Board

Veritas and Cannevert Complete Prestudy Visit of the Puerto Rico Clinical Trial Facility

Veritas Pharma Subsidiary Receives Health Canada Dealer Licence

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $2.16, up 27.81%, on 969,988 volume with 1,172 trades. The stock’s average daily volume over the past 60 days is 392,298 and its 52-week low/high is $0.27/$2.13.

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) and its Revolutionary Technology are Ready for the Cannabis Industry

Uptick Newswire “Stock Day” Interviews CEO of Lexaria on Cannabis Related Products and Recent Bioscience Patents

Lexaria Bioscience Receives U.S. Patent Award for its DehydraTECH(tm) Delivery of THC, NSAIDs, Nicotine and Vitamins

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $1.4323, up 34.54%, on 4,399,914 volume with 3,263 trades. The stock’s average daily volume over the past 60 days is 1,070,173, and its 52-week low/high is $0.16/$1.18.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

CannabisNewsWire Announces Publication on Increased Investment Activity in Cannabis

CannabisNewsWire Announces Publication Discussing Biotech's Leading Role in the Cannabis Industry

NetworkNewsWire Announces Publication Discussing the Production of Quality Cannabinoids with Therapeutic Potential

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

MarketBeat
(FBER) +72.73%

2.

InvestorPlace
(MRGE) +72.55%

3.

CannabisNewsWire
(POTN) +70.51%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251